Login Register Cart 0
Review Article

塞来昔布在癌症治疗和预防中的作用——综述

卷 20, 期 3, 2019

页: [302 - 315] 页: 14

弟呕挨: 10.2174/1389450119666180803121737

价格: $65

摘要

背景与目的：肿瘤微环境中的炎性细胞参与肿瘤形成过程，促进细胞增殖、存活和迁移是公认的。因此，在癌症治疗中使用消炎药物似乎是合理的。与上述问题相关的一个潜在途径是环氧合酶-2抑制，特别是当这种酶的过度表达已被证明发生在癌症组织中，并且也与几种人类恶性肿瘤的预后不良有关。塞来昔布是一种COX-2选择性抑制剂，已被应用20多年，尤其是作为一种抗炎、镇痛和解热药物。然而，迄今为止，它的抗肿瘤性能还没有得到充分的研究。近年来，塞来昔布抗肿瘤作用的研究数量显著增加。绝大多数的出版物是指试图阐明其作用机制的临床前研究。塞来昔布的临床试验主要集中在治疗结肠癌、乳腺癌、肺癌、前列腺癌、胃癌、头颈癌以及家族性腺瘤息肉病等癌前病变。本文试图总结塞来昔布在癌症治疗和预防中的最新研究成果。 结论：临床前和临床研究均显示，塞来昔布在癌症治疗和预防中的作用有着良好的效果，在结肠癌、乳腺癌、前列腺癌和头颈癌中观察到最佳效果。然而，需要更多的临床试验来提供塞来昔布使用的真正的循证临床进展。

关键词: 癌症，塞来昔布，癌症化疗，联合治疗，COX-2，炎症。

« Previous Next »
图形摘要

[1]
Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
[2]
Conaghan PG. A turbulent decade for NSAIDs: Update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int 2012; 32: 1491-502.
[3]
Harris RE, Beebe J, Alshafie GA. Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. J Exp Pharmacol 2012; 4: 91-6.
[4]
Fujii R, Imanishi Y, Shibata K, et al. Restoration of E-cadherin expression by selective Cox-2 inhibition and the clinical relevance of the epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. J Exp Clin Cancer Res 2014; 33: 40.
[5]
Sacchetti A. Cancer cell killing by Celecoxib: Reality or just in vitro precipitation-related artifact? J Cell Biochem 2013; 114: 1434-44.
[6]
Futagami S, Suzuki K, Hiratsuka T, et al. Chemopreventive effect of celecoxib in gastric cancer. Inflammopharmacol 2007; 15: 1-4.
[7]
Chow LW, Loo WT, Yip AY, Ng EL. Acceptable cardiac safety profile of neoadjuvant 5-fluorouracil, epirubicin, cyclophosphamide and celecoxib (FEC-C) for breast cancer: A subanalysis of biomarkers for cardiac injury. Int J Biol Markers 2013; 28: 92-9.
[8]
Xu HB, Shen FM, Lv QZ. Celecoxib enhanced the cytotoxic effect of cisplatin in chemo-resistant gastric cancer xenograft mouse models through a cyclooxygenase-2-dependent manner. Eur J Pharmacol 2016; 776: 1-8.
[9]
Benson P, Yudd M, Sims D, et al. Renal effects of high-dose celecoxib in elderly men with stage D2 prostate carcinoma. Clin Nephrol 2012; 78: 376-81.
[10]
Mohsen V, Mohsen A. The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies. Expert Opin Drug Discov 2014; 9: 255-67.
[11]
Mathew ST, Devi SG, Prasanth VV, Vinod B. Efficacy and safety of cox-2 inhibitors in the clinical management of arthritis: Mini Review. ISRN Pharmacol 2011; 2011: 480291.
[12]
Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 2008; 64: 233-52.
[13]
Ye Y, Liu M, Yuan H, et al. COX-2 regulates Snail expression in gastric cancer via the Notch1 signaling pathway. Int J Mol Med 2017; 40: 512-22.
[14]
Ghanghas P, Jain S, Rana C, Sanyal SN. Chemopreventive action of non-steroidal anti-inflammatory drugs on the inflammatory pathways in colon cancer. Biomed Pharmacother 2016; 78: 239-47.
[15]
Xiang HG, Xie X, Hu FQ, et al. Cyclooxygenase-2 inhibition as a strategy for treating gastric adenocarcinoma. Oncol Rep 2014; 32: 1140-8.
[16]
Egashira I, Takahashi-Yanaga F, Nishida R, et al. Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathway. Cancer Sci 2017; 108: 108-15.
[17]
Ninomiya I, Nagai N, Oyama K, et al. Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum. Oncol Rep 2012; 28: 777-84.
[18]
Garcia M, Velez R, Romagosa C, et al. Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice. BJU Int 2014; 113: E164-77.
[19]
Goswami S, Sharma-Walia N. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: Implications in carcinogenesis. Oncotarget 2016; 7: 58953-74.
[20]
Campillo N, Torres M, Vilaseca A, et al. Role of cyclooxygenase-2 on intermittent hypoxia-induced lung tumor malignancy in a mouse model of sleep apnea. Sci Rep 2017; 7: 44693.
[21]
Kido LA, Montico F, Vendramini-Costa DB, Pilli RA, Cagnon VH. Goniothalamin and celecoxib effects during aging: Targeting Pro-inflammatory mediators in chemoprevention of prostatic disorders. Prostate 2017; 77: 838-.
[22]
Dai ZJ, Ma XB, Kang HF, et al. Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in vitro and in vivo/in vitro and in vivo. Cancer Cell Int 2012; 12: 53.
[23]
Rosas C, Sinning M, Ferreira A, Fuenzalida M, Lemus D. Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy. Biol Res 2014; 47: 27.
[24]
Ghanghas P, Jain S, Rana C, Sanyal SN. Chemoprevention of colon cancer through inhibition of angiogenesis and induction of apoptosis by nonsteroidal anti-inflammatory drugs. J Environ Pathol Toxicol Oncol 2016; 35: 273-89.
[25]
Jendrossek V. Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett 2013; 332: 313-24.
[26]
Ramer R, Walther U, Borchert P, et al. Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib. J Lipid Res 2013; 54: 3116-29.
[27]
Li WW, Long GX, Liu DB, et al. Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity. Pharmazie 2014; 69: 132-7.
[28]
Xu B, Wang Y, Yang J, et al. Celecoxib induces apoptosis but up-regulates VEGF via endoplasmic reticulum stress in human colorectal cancer in vitro and in vivo. Cancer Chemother Pharmacol 2016; 77: 797-806.
[29]
Chiang SL, Velmurugan BK, Chung CM, et al. Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma. Sci Rep 2017; 7: 6235.
[30]
Garg M. Epithelial-mesenchymal transition - activating transcription factors - multifunctional regulators in cancer. World J Stem Cells 2013; 5: 188-95.
[31]
Wang ZL, Fan ZQ, Jiang HD, Qu JM. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling. Carcinogenesis 2013; 34: 638-46.
[32]
Lönnroth C, Andersson M, Arvidsson A, et al. Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun 2008; 8: 5.
[33]
Lönnroth C, Andersson M, Asting AG, Nordgren S, Lundholm K. Preoperative low dose NSAID treatment influences the genes for stemness, growth, invasion and metastasis in colorectal cancer. Int J Oncol 2014; 45: 2208-20.
[34]
Schellhorn M, Haustein M, Frank M, Linnebacher M, Hinz B. Celecoxib increases lung cancer cell lysis by lymphokine activated killer cells via upregulation of ICAM-1. Oncotarget 2015; 6: 39342-56.
[35]
Paznekas WA, Okajima K, Schertzer M, Wood S, Jabs EW. Genomic organization, expression, and chromosome location of the human SNAIL gene (SNAI1) and a related processed pseudogene (SNAI1P). Genomics 1999; 62: 42-9.
[36]
Saito Y, Suzuki H, Imaeda H, et al. The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells. Int J Cancer 2013; 132: 1751-60.
[37]
Abrahão AC, Giudice FS, Sperandio FF, Pinto Junior Ddos S. Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma. J Oral Pathol Med 2013; 42: 793-8.
[38]
Liu M, Li CM, Chen ZF, et al. Celecoxib regulates apoptosis and autophagy via the PI3K/Akt signaling pathway in SGC-7901 gastric cancer cells. Int J Mol Med 2014; 33: 1451-8.
[39]
Liu DB, Hu GY, Long GX, et al. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. Acta Pharmacol Sin 2012; 33: 682-90.
[40]
Pucci B, Kasten M, Giordano A. Cell cycle and apoptosis. Neoplasia 2000; 2: 291-9.
[41]
Saha B, Adhikary A, Ray P, et al. Restoration of tumor suppressor p53 by differentially regulating pro- and anti-p53 networks in HPV-18-infected cervical cancer cells. Oncogene 2012; 31: 173-86.
[42]
Liu HF, Hsiao PW, Chao JI. Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells. Chem Biol Interact 2008; 176: 48-57.
[43]
Katkoori VR, Manne K, Vital-Reyes VS, et al. Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53. Biotech Histochem 2013; 88: 38-46.
[44]
Zhu X, Zhou M, Liu G, et al. Autophagy activated by the c Jun N terminal kinase mediated pathway protects human prostate cancer PC3 cells from celecoxib induced apoptosis. Exp Ther Med 2017; 13: 2348-54.
[45]
Kashiwagi E, Shiota M, Yokomizo A, et al. EP2 signaling mediates suppressive effects of celecoxib on androgen receptor expression and cell proliferation in prostate cancer. Prostate Cancer Prostatic Dis 2014; 17: 10-7.
[46]
Brizzolara A, Benelli R, Venè R, et al. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer. Cancer Lett 2017; 400: 9-17.
[47]
Esbona K, Inman D, Saha S, et al. COX-2 modulates mammary tumor progression in response to collagen density. Breast Cancer Res 2016; 18: 35.
[48]
Ghosh R, Alajbegovic A, Gomes AV. NSAIDs and cardiovascular diseases: role of reactive oxygen species. Oxid Med Cell Longev 2015; 2015: 536962.
[49]
Ong CK, Lirk P, Tan CH, Seymour RA. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res 2007; 5: 19-34.
[50]
Gong L, Thorn CF, Bertagnolli MM, et al. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 2012; 22: 310-8.
[51]
Patrono C. Cardiovascular effects of cyclooxygenase‐2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol 2016; 82: 957-64.
[52]
Chen J, Shen P, Zhang XC, Zhao MD, Zhang XG, Yang L. Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials. Clin Ther 2014; 36: 1253-63.
[53]
Thompson PA, Ashbeck EL, Roe DJ, et al. Celecoxib for the prevention of colorectal adenomas: Results of a suspended randomized controlled trial. J Natl Cancer Inst 2016; 108: djw151.
[54]
Wang LW, Hsiao CF, Chen WT, et al. Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: A phase II TCOG study. J Surg Oncol 2014; 109: 580-5.
[55]
James ND, Sydes MR, Mason MD, et al. STAMPEDE Investigators. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: First results from STAMPEDE (MRC PR08, CRUK/06/019), a randomized controlled trial. Lancet Oncol 2013; 14: e5.
[56]
Perroud HA, Alasino CM, Rico MJ, et al. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: Clinical outcomes and biomarkers of response. Cancer Chemother Pharmacol 2016; 77: 365-74.
[57]
Varga Z, Sabzwari S, Vargova V. Cardiovascular risk of nonsteroidal anti-inflammatory drugs: An under-recognized public health issue. Cureus 2017; 9: e1144.
[58]
Brophy JM. Celecoxib and cardiovascular risks. Expert Opin Drug Saf 2005; 4: 1005-15.
[59]
Fanelli A, Ghisi D, Aprile PL, Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf 2017; 8: 173-82.
[60]
Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. Eur J Intern Med 2015; 26: 285-91.
[61]
Chou CI, Shih CJ, Chen YT, et al. Adverse effects of oral nonselective and cyclooxygenase-2-selective nsaids on hospitalization for acute kidney injury. A nested case-control cohort study. Medicine (Baltimore) 2016; 95: e2645.
[62]
Benson P, Yudd M, Sims D, et al. Renal effects of high-dose celecoxib in elderly men with stage D2 prostate carcinoma. Clin Nephrol 2012; 78: 376-81.
[63]
Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol 2017; 18: 256.
[64]
Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002; 25: 537-44.
[65]
Lee Y, Kim H, Kim W, et al. Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis. J Drug Target 2012; 20: 524-34.
[66]
Gowda R, Kardos G, Sharma A, Singh S, Robertson GP. Nanoparticle-based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma. Mol Cancer Ther 2017; 16: 440-52.
[67]
Allhenn D, Neumann D, Béduneau A, Pellequer Y, Lamprecht AA. “drug cocktail” delivered by microspheres for the local treatment of rat glioblastoma. J Microencapsul 2013; 30: 667-73.
[68]
Fakih MG, Rustum YM. Does celecoxib have a role in the treatment of patients with colorectal cancer? Clin Colorectal Cancer 2009; 8: 11-4.
[69]
No authors listed. Celecoxib: new indication. Colorectal cancer: No preventive benefit. Prescrire Int 2006; 15: 13-5.
[70]
Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-66.
[71]
Solomon SD, McMurray JJ, et al. For the Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 2005; 352: 1071-80.
[72]
Manzano A, P’erez-Segura P. Colorectal cancer chemoprevention: Is this the future of colorectal cancer prevention? Sci World J 2012; 2012: 327341.
[73]
Wang Y, Zhang FC, Wang YJ. The efficacy and safety of non-steroidal anti-inflammatory drugs in preventing the recurrence of colorectal adenoma: A meta-analysis and systematic review of randomized trials. Colorectal Dis 2015; 17: 188-96.
[74]
Veettil SK, Teerawattanapong N, Ching SM, et al. Effects of chemopreventive agents on the incidence of recurrent colorectal adenomas: a systematic review with network meta-analysis of randomized controlled trials. OncoTargets Ther 2017; 10: 2689-700.
[75]
Falandry C, Debled M, Bachelot T, et al. Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: A double-blind phase III GINECO study. Breast Cancer Res Treat 2009; 116: 501-8.
[76]
Mazhar D, Ang R, Waxman J. COX inhibitors and breast cancer. Br J Cancer 2006; 94: 346-50.
[77]
Perroud HA, Rico MJ, Alasino CM, et al. Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. Future Oncol 2013; 9: 451-62.
[78]
Brandão RD, Veeck J, Van de Vijver KK, et al. A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res 2013; 15: R29.
[79]
Liao Z, Komaki R, Milas L, et al. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 2005; 11: 3342-8.
[80]
Arúajo AM, Mendez JC, Coelho AL, et al. Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer. Cancer Invest 2009; 27: 391-6.
[81]
Gore E. Celecoxib and radiation therapy in non-small-cell lung cancer. Oncology 2004; 18: 10-4.
[82]
Koch A, Bergman B, Holmberg E, et al. Swedish Lung Cancer Study Group Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer 2011; 47: 1546-55.
[83]
Edelman MJ, Wang X, Hodgson L, et al. Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non-small-cell lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (Alliance). J Clin Oncol 2017; 35: 2184-92.
[84]
Reckamp KL, Koczywas M, Cristea MC, et al. Randomized phase ii trial of erlotinib in combination with high dose-celecoxib or placebo in patients with advanced non-small cell lung cancer. Cancer 2015; 121: 3298-306.
[85]
Sooriakumaran P, Coley HM, Fox SB, et al. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res 2009; 29: 1483-8.
[86]
Smith MR, Manola J, Kaufman DS, et al. Celecoxib Versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006; 24: 2723-8.
[87]
Mason MD, Clarke NW, James ND, et al. STAMPEDE investigators Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: Long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. J Clin Oncol 2017; 35: 1530-41.
[88]
Kattan J, Bachour M, Farhat F, et al. Phase II trial of weekly docetaxel, zoledronic acid, and celecoxib for castration-resistant prostate cancer. Invest New Drugs 2016; 34: 474-80.
[89]
Jeong Y, Lee JL. Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer. Asia Pac J Clin Oncol 2017; 13: 204-11.
[90]
Futagami S, Suzuki K, Hiratsuka T, et al. Chemopreventive effect of celecoxib in gastric cancer. Inflammopharmacol 2007; 15: 1-4.
[91]
Wang Z, Chen JQ, Liu JL. COX-2 Inhibitors and Gastric Cancer. Gastroenterol Res Pract 2014; 2014: 132320.
[92]
Han X, Li H, Su L, et al. Effect of celecoxib plus standard chemotherapy on serum levels of vascular endothelial growth factor and cyclooxygenase-2 in patients with gastric cancer. Biomed Rep 2014; 2: 183-7.
[93]
Wong BC, Zhang L, Ma JL, et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut 2012; 61: 812-8.
[94]
Rhee JC, Khuri FR, Shin DM. Advances in chemoprevention of head and neck cancer. Oncologist 2004; 9(3): 302-11.
[95]
Gupta B, Johnson NW, Kumar N. Global epidemiology of head and neck cancers: A continuing challenge. Oncology 2016; 91: 13-3.
[96]
Lee DY, Lim JH, Kim YJ, et al. Effect of celecoxib on survival of mobile tongue cancer. Anticancer Res 2015; 35: 4235-41.
[97]
Patil VM, Noronha V, Joshi A, et al. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol 2015; 51: 279-86.
[98]
Patil VM, Chakraborty S, Jithin TK, et al. An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients. South Asian J Cancer 2016; 5: 48-51.
[99]
Patil VM, Noronha V, Joshi A, et al. Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers. Indian J Med Paediatr Oncol 2015; 36: 161-5.
[100]
Lodi G, Franchini R, Warnakulasuriya S, et al. Interventions for treating oral leukoplakia to prevent oral cancer. Cochrane Database Syst Rev 2016; 7: CD001829.
[101]
Saba NF, Hurwitz SJ, Kono SA, et al. Chemoprevention of head and neck cancer with celecoxib and erlotinib: Results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila) 2014; 7: 283-91.
[102]
Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: Targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) Prodrugs. Chem Rev 2016; 116: 3436-86.
[103]
Xu HB, Shen FM, Lv QZ. Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2. Eur J Pharmacol 2015; 769: 1-7.
[104]
Shi L, Zhong D, Gu C, Yu L. Celecoxib antagonizes the cytotoxic effect of carboplatin in human esophageal cancer cells. Nan Fang Yi Ke Da Xue Xue Bao 2014; 34(6): 792-7.
[105]
Chen M, Yu L, Gu C, et al. Celecoxib antagonizes the cytotoxic effect of cisplatin in human gastric cancer cells by decreasing intracellular cisplatin accumulation. Cancer Lett 2013; 329: 189-96.
[106]
Álvarez P, Marchal JA, Boulaiz H, et al. 5-Fluorouracil derivatives: A patent review. Expert Opin Ther Pat 2012; 22: 107-23.
[107]
Wang W, McLeod HL, Cassidy J, Collie-Duguid ES. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemother Pharmacol 2007; 59: 839-45.
[108]
He J, Pei L, Jiang H, et al. Chemoresistance of colorectal cancer to 5-fluorouracil is associated with silencing of the BNIP3 gene through aberrant methylation. J Cancer 2017; 8: 1187-96.
[109]
Rahman M, Selvarajan K, Hasan MR, et al. Inhibition of COX-2 in colon cancer modulates tumor growth and mdr-1 expression to enhance tumor regression in therapy-refractory cancers In vivo. Neoplasia 2012; 14: 624-33.
[110]
Zhang XQ, Sun XE, Liu WD, et al. Synergic effect between 5 fluorouracil and celecoxib on hypoxic gastric cancer cells. Mol Med Rep 2015; 11: 1160-6.
[111]
Zhang XQ, Zhang HM, Sun XE, Yuan ZJ, Feng YG. Inhibitory effects and mechanism of 5-fluorouracil combined with celecoxib on human gastric cancer xenografts in nude mice. Exp Ther Med 2015; 9: 105-11.
[112]
Sung MW, Lee DY, Park SW, et al. Celecoxib enhances the inhibitory effect of 5-FU on human squamous cell carcinoma proliferation by ROS production. Laryngoscope 2017; 127: E117-23.
[113]
Wong SF. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 2005; 27: 684-94.
[114]
Qian M, Qian D, Jing H, et al. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo. Oncol Rep 2014; 32: 1681-8.
[115]
Valverde A, Peñarando J, Cañas A, et al. The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β- catenin signaling axis. Oncotarget 2017; 8: 21754-69.
[116]
Chen Y, Fu L. Mechanisms of acquired resistance to tyrosine kinase inhibitors. Acta Pharm Sin B 2011; 1: 197-207.
[117]
Shin DM, Zhang H, Saba NF, et al. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res 2013; 19: 1244-56.
[118]
Atari-Hajipirloo S, Nikanfar S, Heydari A, Noori F, Kheradmand F. The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: Involvement of COX-2, Caspase-3, VEGF and NF-κB genes expression. Cell Mol Biol (Noisy-le-grand) 2016; 62: 68-74.
[119]
Valverde A, Peñarando J, Cañas A, et al. Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells. PLoS One 2015; 10: e0131363.
[120]
Maji S, Samal SK, Pattanaik L, et al. Mcl-1 is an important therapeutic target for oral squamous cell carcinomas. Oncotarget 2015; 6: 16623-37.
[121]
Patil VM, Noronh V, Joshi A, et al. Metronomic palliative chemotherapy in maxillary sinus tumor. South Asian J Cancer 2016; 5: 56-8.
[122]
Janakiraman H, House RP, Talwar S, et al. Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma. Oncogene 2016; 36: 3137-48.
[123]
Kumar BN, Rajput S, Dey KK, et al. Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC Cancer 2013; 13: 273.
[124]
Cheki M, Yahyapour R, Farhood B, et al. COX-2 in Radiotherapy; a potential target for radioprotection and radiosensitization. Curr Mol Pharmacol 2018; 11(3): 173-83.
[125]
Zhang SX, Qiu QH, Chen WB, Liang CH, Huang B. Celecoxib enhances radiosensitivity via induction of G2-M phase arrest and apoptosis in nasopharyngeal carcinoma. Cell Physiol Biochem 2014; 33: 1484-97.
[126]
Yusup G, Akutsu Y, Mutallip M, et al. Matsubara H. A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. Int J Oncol 2014; 44: 1146-52.
[127]
Han ZQ, Liao H, Shi F, et al. Inhibition of cyclooxygenase-2 sensitizes lung cancer cells to radiation-induced apoptosis. Oncol Lett 2017; 14(5): 5959-65.
[128]
Yang J, Yue JB, Liu J, et al. Effect of celecoxib on inhibiting tumor repopulation during radiotherapy in human FaDu squamous cell carcinoma. Contemp Oncol (Pozn) 2014; 18: 260-7.
[129]
Xu XT, Hu WT, Zhou JY, Tu Y. Celecoxib enhances the radiosensitivity of HCT116 cells in a COX-2 independent manner by up-regulating BCCIP. Am J Transl Res 2017; 9: 1088-100.
[130]
Kim YM, Jeong IH, Pyo H. Celecoxib enhances the radiosensitizing effect of 7-hydroxystaurosporine (UCN-01) in human lung cancer cell lines. Int J Radiat Oncol Biol Phys 2012; 83: e399-407.
[131]
Pal I, Dey KK, Chaurasia M, et al. Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma. Tumour Biol 2016; 37: 6389-402.
[132]
Sun J, Liu NB, Zhuang HQ, et al. Celecoxib-erlotinib combination treatment enhances radiosensitivity in A549 human lung cancer cell. Cancer Biomark 2017; 19(1): 45-0.
[133]
Fu S, Rivera M, Ko EC, et al. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 as a novel approach to enhance radiotherapy. J Cell Sci Ther 2011. 13:1(2). pii: S1-002

Rights & Permissions Print Cite
Article Metrics
136
14
© 2024 Bentham Science Publishers | Privacy Policy